Professional Summary

Professional Overview

Bob Schafer is the Chief Executive Officer (CEO) at Lumos Labs (Lumosity), where he leads the company's strategic vision and directs its day-to-day operations. With a strong background in neuroscience and cognitive research, Schafer is a respected industry expert focused on developing innovative digital therapeutics and cognitive enhancement solutions.

Experience Summary

Current Role

As CEO of Lumos Labs, Schafer is responsible for driving the company's growth and overseeing the development and commercialization of its cognitive training platform, Lumosity. In his previous role as Chief Science Officer (CSO), he was instrumental in advancing the company's research and data-driven approach to product innovation. Under his leadership, Lumos Labs has expanded its portfolio of digital therapeutics and established strategic partnerships with leading healthcare organizations.

Career Progression

Prior to joining Lumos Labs, Schafer co-founded Prophecy Sciences, a YC-backed startup focused on cognitive assessment and training. As the Founder and CEO, he led the company's successful acquihire by Lumos Labs in 2015. Earlier in his career, Schafer held a Postdoctoral Associate position at the Massachusetts Institute of Technology, where he conducted groundbreaking research in the field of neuroscience.

Academic Background

Schafer holds a Ph.D. in Neuroscience from the Stanford University School of Medicine, where he specialized in the neural mechanisms underlying cognitive processes and human performance.

Areas of Expertise

• Digital therapeutics and cognitive enhancement solutions

• Neuroscience and cognitive research

• Product development and innovation

• Strategic leadership and business strategy

• Startup and growth-stage management

Professional Impact

Throughout his career, Schafer has been at the forefront of developing evidence-based cognitive training programs and digital health solutions. As the CEO of Lumos Labs, he has led the company's expansion into new markets and the launch of its DTx (Digital Therapeutics) division, which aims to address the growing demand for non-pharmacological interventions for cognitive and mental health conditions.

Conclusion

With his extensive experience in neuroscience, cognitive research, and digital health, Bob Schafer is a visionary leader who is driving the transformation of the cognitive enhancement and digital therapeutics landscape. As Lumos Labs' CEO, he is poised to continue the company's growth and solidify its position as a leading innovator in the field of cognitive health and performance.